24
Participants
Start Date
January 4, 2023
Primary Completion Date
June 15, 2026
Study Completion Date
June 15, 2026
Naldemedine
Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)
COMPLETED
Chu de Caen, Caen
NOT_YET_RECRUITING
University Center Mother Theresa , Hospital - Onco-hematology department, Tirana
RECRUITING
Yeolyan Hematology. , and Oncology Center -, Yerevan
COMPLETED
CHU Saint-Pierre Clinical Trials Unit, Brussels
COMPLETED
Universitair Ziekenhuis Brussel (UZBrussel) - Department of Anesthesiology and Perioperative Medicine, Brussels
COMPLETED
University Hospitals Leuven Pediatrisch hemato-oncology, Leuven
RECRUITING
University Clinical Hospital , Mostar, Mostar
COMPLETED
Hôpital Béclère Service de Pédiatrie Centre de Référence des Maladies Héréditaires du Métabolisme Hépatique (CRMHMH), Clamart
COMPLETED
Hôpital Jeanne de Flandre Antenne du CIC pédiatrique - Niveau 0 CHU de Lille, Lille
COMPLETED
Hôpital Armand Trousseau Service Hématologie et Oncologie Pédiatrique, Paris
COMPLETED
Instituto Nazionale dei Tumori, Milan
COMPLETED
Citta della Salute e della Scienza di Torino, Torino
COMPLETED
Maternal and Child Health Institute IRCCS Burlo Garofolo, Pain and pediatric palliative care service, Trieste
NOT_YET_RECRUITING
National Center for Child Health and Development, Tokyo
RECRUITING
PHI University Clinic for Children's , Surgery, Skopje
RECRUITING
University Clinic for Childrens Diseases , Department of Oncology, Hematology and , Malignant Hemopathy, Skopje
Lead Sponsor
Shionogi
INDUSTRY